Online inquiry

IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6424MR)

This product GTTS-WQ6424MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza A infection research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6424MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2928MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG888
GTTS-WQ9098MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMCgp100
GTTS-WQ8942MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ9255MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ4516MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ4961MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA c2G4-N
GTTS-WQ5302MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ4412MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-663513
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW